# AAPS360-2023
Supporting materials for conference poster M1030-10-64
![metrm](./pics/metrum_new_logo greyscale.png)

## Link to supporting code 
Matthew Wiens created [this page](https://github.com/metrumresearchgroup/confounded-exposure-metrics) and also wrote a perspective paper (submitted, see reference, below), which was the premise of the poster

## References

### Matthew Wiens supporting publication: 
Wiens M, French J, Rogers J. Perspective: Confounded Exposure Metrics. CPT Pharmacometrics Syst Pharmacol 2023 (submitted)

### Further reading on causal inference and DAGs: 
1. [Directed acyclic graphs: a tool for causal studies in paediatrics](https://rdcu.be/dmIrW)
  Williams, T.C., Bach, C.C., Matthiesen, N.B. et al. Directed acyclic graphs: a tool for causal studies in paediatrics. Pediatr Res 84, 487–493 (2018). https://doi.org/10.1038/s41390-018-0071-3

2. [An introduction to causal inference for pharmacometricians](https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/psp4.12894)
  Rogers JA, Maas H, Pitarch AP. An introduction to causal inference for pharmacometricians. CPT Pharmacometrics Syst Pharmacol 2023;12:27–40.
  
### Guidelines for exposure endpoints for E-R in oncology: 
1. [A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169901/) Ruiz-Garcia A, Baverel P, Bottino D, Dolton M, Feng Y, González-García I, Kim J, Robey S, Singh I, Turner D, Wu SP, Yin D, Zhou D, Zhu H, Bonate P. A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development. J Pharmacokinet Pharmacodyn. 2023 Jun;50(3):147-172. doi: 10.1007/s10928-023-09850-2. Epub 2023 Mar 4. PMID: 36870005; PMCID: PMC10169901.


### Analyses that use CavgTE as exposure endpoint: 
1. Tran BD, Li J, Ly N, et al. Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma. Cancer Chemother Pharmacol 2023;91:179–89.
2. Hamuro L, Hu Z, Passarell J, et al. Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma. Clin Cancer Res 2022;28:1603–13.
3. Center for Drug Evaluation and Research, US Food and Drug Administration. Clinical Pharmacology and Biopharmaceutics Review: Application Number 761040Orig1s000; Inotuzumab Ozogamicin. 2016.https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761040Orig1s000MultidisciplineR.pdf (accessed 1 May 2023).
4. Center for Drug Evaluation and Research, US Food and Drug Administration. Clinical Pharmacology and Biopharmaceutics Review: Application Number 212306Orig1s000; Selinexor. 2019.https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000MultidisciplineR.pdf (accessed 1 May 2023).